Oxygen Double Bonded To A Ring Carbon Of The Cyclopentanohydrophenanthrene Ring System Patents (Class 514/177)
-
Publication number: 20150140127Abstract: Provided is a method for detecting injury to the brain comprising: a) determining the level of a tight junction (TJ) protein in exosomes isolated from a test sample from a subject, wherein the TJ protein is occludin, claudin-3, claudin-5, claudin-12, ZO-1, ZO-2, ZO-3, JAM-A, JAM-B or JAM-C, or any combination thereof; b) comparing the level of the TJ protein in the test sample to the level of the TJ protein in a control sample, wherein an elevated level of the TJ protein in the test sample relative to the level of the TJ protein in the control sample indicates that the subject has an injury to the brain.Type: ApplicationFiled: June 25, 2013Publication date: May 21, 2015Applicant: TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: Servio H. Ramirez, Slava Rom, Yuri Persidsky
-
Publication number: 20150141350Abstract: A nanodevice composition including N-acetyl cysteine linked to a dendrimer, such as a PAMAM dendrimer or a multiarm PEG polymer, is provided. Also provided is a nanodevice for targeted delivery of a compound to a location in need of treatment. The nanodevice includes a PAMAM dendrimer or multiarm PEG polymer, linked to the compound via a disulfide bond. There is provided a nanodevice composition for localizing and delivering therapeutically active agents, the nanodevice includes a PAMAM dendrimer or multiarm PEG polymer and at least one therapeutically active agent attached to the PAMAM dendrimer or multiarm PEG polymer.Type: ApplicationFiled: September 4, 2014Publication date: May 21, 2015Inventors: Rangaramanujam M. Kannan, Sujatha Kannan, Roberto Romero, Raghavendra S. Navath, Hui Dai, Anupa R. Menjoge
-
Publication number: 20150133382Abstract: The present invention relates to novel genetic markers associated with endometriosis and risk of developing endometriosis, and methods and materials for determining whether a human subject has endometriosis or is at risk of developing endometriosis and the use of such risk information in selectively administering a treatment that at least partially prevents or compensates for an endometriosis related symptom.Type: ApplicationFiled: January 12, 2015Publication date: May 14, 2015Applicant: JUNEAU BIOSCIENCES, LLCInventors: Kenneth Ward, Rakesh N. Chettier, Hans Albertsen
-
Patent number: 9029355Abstract: In certain embodiments, the invention is directed to composition comprising stable particles comprising ganaxolone, wherein the volume weighted median diameter (D50) of the particles is from about 50 nm to about 500 nm.Type: GrantFiled: November 22, 2013Date of Patent: May 12, 2015Assignee: Marinus PharmaceuticalsInventors: Kenneth Shaw, Mingbao Zhang
-
Publication number: 20150112116Abstract: Provided herein are methods comprising providing a tyrosine derivative and a solid particulate material (and, optionally, melanin) and applying force to said tyrosine derivative and said solid particulate material for a time and under conditions effective to impregnate at least one of said tyrosine derivative and said solid particulate material with the other of said tyrosine derivative and said solid particulate material. The invention also provides compositions comprising at least one of a tyrosine derivative impregnated with a solid particulate material and a solid particulate material impregnated with a tyrosine derivative.Type: ApplicationFiled: October 24, 2013Publication date: April 23, 2015Inventor: STEVEN HOFFMAN
-
Publication number: 20150111834Abstract: The disclosure provides a recipe for in-situ gel, formed by dissolving at least one polymer and at least one gel prevention agent in a polar solvent to form a solution and placing the solution in a condition for in-situ forming gels. The disclosure also provides an implant and a drug delivery system formed by the recipe.Type: ApplicationFiled: September 17, 2014Publication date: April 23, 2015Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTEInventors: Felice CHENG, Maggie J.M. LU, Yi-Ju KO, Min-Ying LIN, Shuen-Hsiang CHOU
-
Patent number: 9011908Abstract: Fill materials for hydrophobic drugs, such as progesterone, and methods of making and using thereof are described herein. The fill material contains the hydrophobic drug dissolved in one or more fatty acids. The concentration of the hydrophobic drug is typically from about 7% to about 50% by weight of the fill material. The concentration of the one or more fatty acids is from about 60% to about 95% by weight of the carrier. The formulation also contains an organic acid and one or both of one or more pharmaceutically acceptable alcohols and one or more pharmaceutically acceptable mono-, di-, or triesters of medium or long chain fatty acids. The fill material can be encapsulated in a hard or soft capsule. The formulations described herein have a higher dissolution rate and faster onset of dissolution compared to micronized progesterone suspended in an oil and thus should have increased bioavailability in vivo.Type: GrantFiled: April 1, 2010Date of Patent: April 21, 2015Assignee: Banner Life Sciences LLCInventors: Zhi Liu, Saujanya L. Gosangari, Dana S. Toops, Aqeel Fatmi
-
Publication number: 20150098978Abstract: A tablet that includes a solid solution of soluble fiber and one or more sugar alcohols, the solid solution having a glass transition temperature of less than 40° C., and one or more additives dispersed in the solid solution such that at least one additive is released from the tablet when the tablet is chewed or dissolved within an oral cavity.Type: ApplicationFiled: October 3, 2014Publication date: April 9, 2015Inventors: Feng Gao, Diane L. Gee, Phillip M. Hulan, Shuzhong Zhuang, William J. Burke, Gerd Kobal
-
Publication number: 20150094289Abstract: Provided herein are small molecules that have a neuroprotective or modulatory effect in the nervous system. The small molecules provided herein modulate dopaminergic neuronal activity. Also provided herein are methods of for the prophylaxis of or preventing the progression of Parkinson's Disease (PD).Type: ApplicationFiled: June 3, 2013Publication date: April 2, 2015Inventors: Rudolfo Gonzalez, Ibon Garitaonandia, Ruslan Semechkin
-
Publication number: 20150094291Abstract: The invention provides a method for improving the emotional development of an infant by performing controlled exposure of the infant aged less than six months old to human fear pheromone, preferably with visual fear stimuli, so that the natural synaptic connections in the brain associated with normal fear mechanisms are stimulated and exercised. This can reduce the occurrence of mental illness later in life, in particular reduce the occurrence of schizophrenia. Advantageously the exposure to fear pheromone and visual fear stimuli is terminated and followed by comforting stimuli such as feeding, physical contact, or comforting or happy visual or audible stimuli such as laughter.Type: ApplicationFiled: October 2, 2013Publication date: April 2, 2015Applicant: Opendot Research Co LimitedInventor: Derek John GOLDSMITH
-
Publication number: 20150094288Abstract: A method of treating a solid tumor in a mammal by inhibiting angiogenesis, including administering to the mammal which has a solid tumor selected from the group consisting of breast carcinoma, lung carcinoma, prostate carcinoma, colon carcinoma, ovarian carcinoma, neuroblastoma, central nervous system tumor, multiform glioblastoma and melanoma; a composition including brassinosteroids of general formula (I) wherein can be a single or double bond and the configurations of carbon atoms C22 and C23 respectively linked to the substituents HO are S for both carbon atoms and a pharmaceutically acceptable additive.Type: ApplicationFiled: December 14, 2012Publication date: April 2, 2015Applicant: CONSEJO NACIONAL DE INVESTIGACIONES CIENTIFICAS Y TECHNICAS (CONICET)Inventors: Javier Alberto Ramirez, Flavia Mariana Michelini, Lydia Raquel Galagovsky, Alejandro Berra, Laura Edith Alche
-
Patent number: 8993520Abstract: The invention is directed to a transdermal drug delivery composition which includes at least one physiologically active agent; and at least one volatile solvent; and at least one viscosity modulating agent. The invention extends to methods of administering such a composition to a subject and treatment of subjects using the composition.Type: GrantFiled: June 25, 2010Date of Patent: March 31, 2015Assignee: Acrux DDS Pty LtdInventors: Tony Dipietro, Andrew Humberstone, Igor Gonda, Adam Watkinson, Kerrie Setiawan, Nina Wilkins
-
Publication number: 20150079189Abstract: In one embodiment, the present application discloses synthetic LDL nanoparticles comprising mixtures of components selected from the group consisting of phospholipids, triglycerides, cholesterol ester and free cholesterol; optionally further comprising an agent selected from the group consisting of natural antioxidants, ubiquinol and vitamin E, and methods for preparing the synthetic nanoparticles. The disclosed synthetic LDL nanoparticles are capable of selectively delivering lipophilic drugs and prodrugs to cellular targets expressing LDL receptors after intra venous injection.Type: ApplicationFiled: September 13, 2014Publication date: March 19, 2015Applicant: Arbor Therapeutics, LLCInventors: James D. McChesney, Igor Nikoulin, Steve J. Bannister, Douglas L. Rodenburg
-
Patent number: 8969327Abstract: The disclosure relates to novel C4 and C6 substituted androst-4-ene diones as well as andros-1,4-diene diones and derivatives thereof, their process of preparation, pharmaceutical compounds containing them, and the use of said compounds for the treatment of hormone-related disorders in mammals. This includes hormone-dependent cancers, particularly those caused by elevated levels of estrogen and its intermediates. These compounds can also be used in the treatment of other hormone-related disorders, including benign prostatic hyperplasia, cardiovascular disease, and neurodegenerative disorders.Type: GrantFiled: April 7, 2011Date of Patent: March 3, 2015Assignees: Emory University, The Research Foundation of State of New York, Hauptman-Woodward Medical Research InstituteInventors: Huw Davies, Dabashis Ghosh, Daniel Morton
-
Publication number: 20150056269Abstract: The present invention relates to a novel galenic form of cholesterol derivative. More particularly the invention relates to liposomes comprising at least one cholesterol derivative and compositions comprising said liposomes.Type: ApplicationFiled: August 22, 2012Publication date: February 26, 2015Applicant: TROPHOSInventors: Corinne Chaimbault, Magali Michaud, Patrick Berna, Sophie Schaller, Firas Bassissi, Simon Eastman
-
Method for post coital contraception in overweight or obese female subjects using ulipristal acetate
Patent number: 8962603Abstract: The invention provides a method for providing post coital contraception in a female subject, comprising providing the subject with a therapeutically effective amount of ulipristal acetate, wherein the female subject is overweight or obese.Type: GrantFiled: December 1, 2010Date of Patent: February 24, 2015Assignee: Laboratoire HRA-PharmaInventors: Delphine Levy, Andre Ulmann, Henri Camille Mathe, Erin Gainer -
Publication number: 20150050355Abstract: A particulate SAE-CD composition is provided. The SAE-CD composition has an advantageous combination of physical properties not found in known solid forms of SAECD. In particular, the SAE-CD composition possesses an advantageous physicochemical and morphological property profile such that it can be tailored to particular uses. The SAE-CD composition of the invention has improved flow and dissolution performance as compared to known compositions of SAE-CD.Type: ApplicationFiled: September 17, 2014Publication date: February 19, 2015Inventors: James D. Pipkin, Gerold L. Mosher, Douglas B. Hecker
-
Patent number: 8957115Abstract: Pheromone compositions based on a combination of squalene, linoleic acid and 1-docosanol are described. The compositions are useful for behavior modification in mammals that exhibit undesirable or harmful stress-related behaviors.Type: GrantFiled: May 28, 2013Date of Patent: February 17, 2015Assignee: Sergeant's Pet Care Products, Inc.Inventors: Larry Nouvel, Cuong Tu Ba, Luis Rios
-
Publication number: 20150044291Abstract: Endometriosis, including endometriosis externa, endometrioma, adenomyosis, adenomyomas, adenomyotic nodules of the uterosacral ligaments, and endometriotic nodules, such as scar endometriosis are effectively treated by the intralesional administration, including transvaginal, endoscopic or open surgical administration including via laparotomy, of a progestogen. Compositions therefor also are provided.Type: ApplicationFiled: October 27, 2014Publication date: February 12, 2015Inventor: Mirudhubashini GOVINDARAJAN
-
Patent number: 8912174Abstract: The invention involves methods and formulations for treating or preventing rhinosinusitis, including fungus-induced rhinosinusitis in mammals. In one embodiment, the formulation of the present invention comprises a steroidal anti-inflammatory agent having a specific particle size distribution profile. The formulation may also comprise an antifungal agent, antibiotic or antiviral agent.Type: GrantFiled: September 4, 2003Date of Patent: December 16, 2014Assignee: Mylan Pharmaceuticals Inc.Inventor: Imtiaz Chaudry
-
Publication number: 20140349984Abstract: Methods of treating a subject with a traumatic central nervous system injury, more particularly, a traumatic brain injury, are provided. The methods comprise a therapy comprising a constant or a two-level dosing regime of progesterone. In one method, a subject in need thereof is administered at least one cycle of therapy, wherein the cycle of therapy comprises administering a therapeutically effective two-level intravenous dosing regime of progesterone. The two-level dosing regime comprises a first time period, wherein a higher hourly dose of progesterone is administered to the subject, followed by a second time period, wherein a lower hourly dose of progesterone is administered to the subject.Type: ApplicationFiled: January 2, 2014Publication date: November 27, 2014Applicant: EMORY UNIVERSITYInventors: Stuart W. Hoffman, Arthur L. Kellermann, Donald G. Stein, David W. Wright, Douglas W. Lowery-North
-
Patent number: 8895053Abstract: The subject invention provides improved testosterone gel formulations.Type: GrantFiled: January 18, 2012Date of Patent: November 25, 2014Assignee: Ferring B.V.Inventors: Arnaud Grenier, Dario N. Carrara
-
Publication number: 20140343027Abstract: The present invention relates to the formulation of steroids, including neurosteroids (e.g., allopregnanolone (ALP)) in edible oils to enhance their absorption when administered, e.g., orally or transmucosally to a patient.Type: ApplicationFiled: September 21, 2012Publication date: November 20, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventor: Michael A. Rogawski
-
Publication number: 20140335193Abstract: The invention relates to a controlled-release injectable microparticle comprising a polyvinyl alcohol polymer and one or more hormones, in particular progesterone. Said microparticle induces estrus in female mammals after a single application. The invention also relates to a method for obtaining the microparticle.Type: ApplicationFiled: May 11, 2012Publication date: November 13, 2014Applicants: CONICET - CONS. NAC. DE INVESTIGACIONES CIENTIFICAS Y TECNICAS, IPCVA- INSTITUTO DE PROMOCION DE LA CARNE VACUNA ARGENTINA, UNL UNIVERSIDAD NACIONAL DEL LITORALInventors: Ignacio Rintoul, Juan Manuel Badano, Ricardo Grau
-
Publication number: 20140335133Abstract: Described are sterile, ready-to-use, pharmaceutical oil-in-water emulsion compositions for parenteral administration comprising: 0.015 to 0.5% wt/vol progesterone; 0.5 to 10% wt/vol oil, wherein the oil comprises at least 85% wt./wt. triglyceride; 0.0425 to 4.1% wt/vol phospholipid; 80-99.4% wt/vol aqueous medium; wherein the composition has an osmolality in the range of 200-1000 mOsm/kg. Also described are methods of making such compositions and method of using such compositions in therapeutic or prophylactic treatment, such as treatments comprising intravenous administration of the pharmaceutical composition.Type: ApplicationFiled: May 16, 2014Publication date: November 13, 2014Applicant: BESINS Healthcare Luxembourg SARLInventors: Georg Achleitner, Eva-Maria Hoiser, Laura Pickersgill
-
Publication number: 20140329783Abstract: Hormone replacement therapies are provided comprising solubilized progesterone alone and optionally with an estrogen, cyclic/sequential and continuous-combined dosing, and administered via transdermal HRT delivery systems.Type: ApplicationFiled: January 25, 2013Publication date: November 6, 2014Inventors: Brian A. Bernick, Julia M. Amadio, Peter H.R. Persicaner, Janice Louise Cacace, Neda Irani
-
Patent number: 8877236Abstract: New liposomes are described, comprising: (i) phosphatidic acid and/or cardiolipin; (ii) apolipoprotein E (ApoE) or derivatives thereof. The so modified liposomes, administered systemically, obtain a dramatic in-vivo reduction of the amyloid plaque in the central nervous system, allowing an effective treatment of neurodegenerative diseases, in particular Alzheimer's disease.Type: GrantFiled: June 28, 2012Date of Patent: November 4, 2014Assignee: Universita Degli Studi di Milano-BicoccaInventors: Massimo Masserini, Francesca Re, Giulio Sancini, Gianluigi Forloni, Mario Salmona
-
Patent number: 8865200Abstract: Disclosed are sustained release compositions for vaginal or transdermal administration that contain a progesterone receptor modulator such as CDB-2914 (also referred to as VA-2914), and methods of using them for long term contraception or therapeutic purposes. Also disclosed are methods for making the compositions.Type: GrantFiled: July 8, 2005Date of Patent: October 21, 2014Assignee: Laboratoire HRA PharmaInventors: Regine Sitruk-Ware, Yun-Yen Tsong
-
Publication number: 20140296191Abstract: The present invention relates to pharmaceutical compositions of various pharmaceutical actives, especially lyophilic and hydrophilic actives containing Diethylene glycol monoethyl ether or other alkyl derivatives thereof as a primary vehicle and/or to pharmaceutical compositions utilizing Diethylene glycol monoethyl ether or other alkyl derivatives thereof as a primary vehicle or as a solvent system in preparation of such pharmaceutical compositions. The pharmaceutical compositions of the present invention are safe, non-toxic, exhibits enhanced physical stability compared to conventional formulations containing such pharmaceutical actives and are suitable for use as injectables for intravenous and intramuscular administration, as well as for use as a preformed solution/liquid for filling in and preparation of capsules, tablets, nasal sprays, gargles, dermal applications, gels, topicals, liquid oral dosage forms and other dosage forms.Type: ApplicationFiled: April 2, 2014Publication date: October 2, 2014Applicant: THEMIS MEDICARE LIMITEDInventors: Dinesh Shantilal PATEL, Sachin Dinesh PATEL, Shashikant Prabhudas KURANI, Madhavlal Govindlal PATEL
-
Publication number: 20140296198Abstract: Biomarkers associated with anti-estrogen sensitivity in cancers, methods for detecting and quantitating the biomarkers, and methods for treating cancer patients that exhibit the biomarkers are provided. The biomarkers are activated estrogen receptor foci (AEF) found in the nuclei of certain tumor cells. The methods provide new information to guide the intention to treat patients with anti-estrogens, allowing selection of individual patients and patient populations that are likely to respond to treatment. Also provided are methods for screening an antitumor drug or antitumor drug candidate for AEF inactivating activity. Such methods are useful to identify additional AEF-active drugs, including anti-estrogens, which may be candidates for use in treating AEF-positive tumors according to the methods of the invention.Type: ApplicationFiled: November 1, 2012Publication date: October 2, 2014Inventor: Erard Gilles
-
Publication number: 20140296195Abstract: Use of compounds disclosed herein, typically progesterone or analog or derivative thereof, in the treatment of central nervous system cancers, specifically neuroblastoma and glioblastoma is provided. The treatment offers a reduced toxicity as compared to the currently available chemotherapeutic agents. The progesterone may be administered alone or in combination with, or in conjunction with other therapeutic agents.Type: ApplicationFiled: June 11, 2014Publication date: October 2, 2014Inventors: Donald G. Stein, Iqbal Sayeed, Fahim Atif
-
Publication number: 20140287030Abstract: In one aspect, the invention relates methods and compositions for treating parasitic diseases, for example, leishmaniasis. In a further aspect, the compounds of the methods and compositions are isolated from Pentalinon andrieuxii. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: ApplicationFiled: June 9, 2014Publication date: September 25, 2014Applicant: OHIO STATE INNOVATION FOUNDATIONInventors: Abhay R. Satoskar, James R. Fuchs, Alan Douglas Kinghorn, Li Pan, Claudio M. Lezama-Davila, Eric Bachelder
-
Publication number: 20140271884Abstract: Compositions comprising water-insoluble steroids encapsulated into nanoparticle forms are provided. Methods of preparing water-insoluble steroids encapsulated in a nanoparticle form are provided. Methods of treating disease by delivering a water-insoluble steroid encapsulated into nanoparticle form to a patient in need thereof are provided.Type: ApplicationFiled: October 25, 2012Publication date: September 18, 2014Inventors: Robert K. Prud'homme, Carlos E. Figueroa
-
Patent number: 8828981Abstract: A method for treating or preventing spontaneous preterm birth in pregnant women and improving neonatal morbidity and mortality. The method includes administering to a pregnant woman in need thereof an effective amount of progesterone sufficient to prolong gestation by minimizing the shortening or effacing of her cervix. Treatment and prophylaxis with progesterone in pregnant women having symptoms of short cervix has been clinically shown to increase neonatal health.Type: GrantFiled: February 1, 2008Date of Patent: September 9, 2014Inventors: George Creasy, John M. O'Brien, Jr., Emily A. DeFranco, Kenneth N. Muse
-
Publication number: 20140248367Abstract: Provided herein are dry pharmaceutical compositions for transmucosal delivery, comprising spray-dried particles that include pharmaceutically active agent nanoparticles, a binder, and a pharmaceutically acceptable carrier, where the active agent nanoparticles have an average particle size diameter prior to spray-drying of less than about 1 ?m, and wherein up to 10% of the spray-dried particles have a particle size of less than 10 ?m; at least 50% of the spray-dried particles have a particle size of at least about 15 ?m; and at least 90% of the spray-dried particles have a particle size of up to about 55 ?m. Also provided are methods for making such pharmaceutical compositions and therapeutic methods comprising transmucosally administering the compositions, such as intranasally or intravaginally.Type: ApplicationFiled: March 3, 2014Publication date: September 4, 2014Applicant: Besins Healthcare Luxembourg SARLInventors: Maynard Emanuel Lichty, Garry T. Gwozdz
-
Publication number: 20140242161Abstract: The present invention relates to soft gelatin capsules characterized in that the shell includes a cyclodextrin and in that the filling material contains a liposoluble drug capable of forming a complex with said cyclodextrin for improving the solubility of the active ingredient upon disintegration of the soft gelatin capsule.Type: ApplicationFiled: April 7, 2014Publication date: August 28, 2014Inventors: Giorgio ZOPPETTI, Maurizio MARCHIORRI
-
Publication number: 20140234428Abstract: The invention, a transdermal delivery method, relates to penetration-enhancing pharmaceutical compositions comprising a novel, stable mixture of cetylated esters, cetyl or stearyl alcohols, polar solvents and surfactants, which, under appropriate conditions, combine into amphiphilic nanoparticles within a stabilized liquid dispersion for use in delivery of medicinal agents through the skin. The term cetosomes is used to describe these particles in order to differentiate them from other nanoparticles, such as niosomes, cerasomes, polymeric micelles, dendrimers, liposomes, lipoids, solid lipid nanoparticles and other particles. The self-assembling cetosomes, with both ionic and nonionic points of attraction, incorporate and concentrate a variety of different bioactive agents of interest and demonstrate stable properties with similarities to colloidal molecular structures. The compositions enhance topical transdermal fluxes of bioactives without permanently disrupting natural skin barrier function.Type: ApplicationFiled: February 15, 2013Publication date: August 21, 2014Applicant: Cymbiotics, Inc.Inventors: Raj R. Barathur, Jack Bain Bookout
-
NEUROACTIVE 19-ALKOXY-17-SUBSTITUTED STEROIDS, PRODRUGS THEREOF, AND METHODS OF TREATMENT USING SAME
Publication number: 20140235600Abstract: The present disclosure is generally directed to neuroactive 19-alkoxy-17-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.Type: ApplicationFiled: December 18, 2013Publication date: August 21, 2014Applicant: Washington UniversityInventors: Douglas Covey, Albert Jean Robichaud -
Publication number: 20140235595Abstract: Disclosed herein are cocrystals of progesterone and a coformer containing a six-membered aromatic ring having at least one substituent possessing a carbonyl functionality. Cocrystals of progesterone and a coformer selected from vanillic acid, benzoic acid, salicylic acid, cinnamic acid, or vanillin are also disclosed herein.Type: ApplicationFiled: September 4, 2013Publication date: August 21, 2014Applicant: Aptuit, Inc.Inventors: Ekaterina ALBERT, Patricia ANDRES, Melanie Janelle BEVILL, Jared SMIT, Jennifer NELSON
-
Patent number: 8809308Abstract: Long term storage stable budesonide-containing solutions are disclosed. The solutions can include budesonide or a pharmaceutically acceptable salt thereof, cromolyn sodium, antioxidizing agent, benzoic acid, and a pharmaceutically acceptable fluid including propylene glycol and water. Kits including the long term storage stable budesonide-containing solutions and methods of treating ulcerative colitis are also disclosed.Type: GrantFiled: November 11, 2013Date of Patent: August 19, 2014Assignee: SciDose, LLCInventors: Nagesh R. Palepu, Philip Christopher Buxton
-
Publication number: 20140206657Abstract: Provided herein are bile acid analogues and derivatives, methods of synthesizing bile acid analogues and derivatives and their use in treating diabetes and liver disease.Type: ApplicationFiled: January 21, 2014Publication date: July 24, 2014Applicant: City of HopeInventors: Donna Yu, Barry Forman, Wendong Huang, Kyle Sousa
-
Publication number: 20140206635Abstract: A metal-salen complex compound, which exhibits excellent noninvasiveness and can be efficiently transferred to an affected site, a local anesthetic containing this metal-salen complex compound, and an antineoplastic drug containing this metal-salen complex compound are provided. Regarding the metal-salen complex compound, a metal atom part in each of two molecules of a metal-salen complex or a derivative of the metal-salen complex is dimerized via water, and the metal-salen complex compound is mixed with a base to produce an ointment.Type: ApplicationFiled: May 10, 2012Publication date: July 24, 2014Applicants: IHI CORPORATIONInventors: Yoshihiro Ishikawa, Haruki Eguchi
-
Publication number: 20140200200Abstract: The invention relates to an antagonist of CB1 receptor for use in the treatment of a pathologic condition or disorder selected from the group consisting of bladder and gastrointestinal disorders; inflammatory diseases; cardiovascular diseases; nephropathies; glaucoma; spasticity; cancer; osteoporosis; metabolic disorders; obesity; addiction, dependence, abuse and relapse related disorders; psychiatric and neurological disorders; neurodegenerative disorders; autoimmune hepatitis and encephalitis; pain; reproductive disorders and skin inflammatory and fibrotic diseases.Type: ApplicationFiled: May 18, 2012Publication date: July 17, 2014Applicants: UNIVERSITE DE BORDEAUX I, INSERM (Institut National de la Sante et de la Recherche Medicale), UNIV DE BORDEAUX II VICTOR SEGALENInventors: Pier Vincenzo Piazza, Monique Vallee, Giovanni Marsicano, Francois-Xavier Felpin, Luigi Bellocchio, Daniela Cota, Jean-Michel Revest, Sergio Vitiello, Umberto Spampinato, Rafael Maldonado
-
Patent number: 8778915Abstract: Use of compounds disclosed herein, typically progesterone or analog or derivative thereof, in the treatment of central nervous system cancers, specifically neuroblastoma and glioblastoma is provided. The treatment offers a reduced toxicity as compared to the currently available chemotherapeutic agents. The progesterone may be administered alone or in combination with, or in conjunction with other therapeutic agents.Type: GrantFiled: March 4, 2013Date of Patent: July 15, 2014Assignee: Emory UniversityInventors: Donald G. Stein, Iqbal Sayeed, Fahim Atif
-
Publication number: 20140187481Abstract: A pharmaceutically delivery system is described comprising a pharmaceutically active agent and acidified nitrite as an agent to produce local production of nitric oxide at the skin surface. The dosage form may be in any pharmaceutically acceptable carrier means and comprises an acidifying agent adapted to reduce the pH at the environment. In one embodiment, a barrier consisting of a membrane allows diffusions of the anaesthetic and nitrite ions while preventing direct contact of the skin and acidifying agent.Type: ApplicationFiled: July 3, 2013Publication date: July 3, 2014Inventors: Arthur Tudor Tucker, Nigel Benjamin
-
Publication number: 20140187524Abstract: Pregn-4-en-20-yn-3?-one is useful in the treatment of depressive disorders by nasal administration.Type: ApplicationFiled: December 19, 2013Publication date: July 3, 2014Applicant: PHERIN PHARMACEUTICALS, INC.Inventor: LOUIS MONTI
-
Publication number: 20140187855Abstract: In some aspects, the present invention provides surgical procedures that comprise applying compositions into and/or onto tissue, including supporting tissues (e.g., ligaments, connective tissue, muscles, etc.) for pelvic organs, among other tissues. In other aspects, the present disclosure pertains to compositions that are useful for performing such procedures. In still other aspects, the present disclosure pertains to kits that are useful for performing such procedures.Type: ApplicationFiled: December 23, 2013Publication date: July 3, 2014Applicant: Boston Scientific Scimed, Inc.Inventors: Sandra Nagale, Mark W. Boden, Andrew Dolan
-
Patent number: 8765149Abstract: Described are sterile, ready-to-use, pharmaceutical oil-in-water emulsion compositions for parenteral administration comprising: 0.015 to 0.5% wt/vol progesterone; 0.5 to 10% wt/vol oil, wherein the oil comprises at least 85% wt./wt. triglyceride; 0.0425 to 4.1% wt/vol phospholipid; 80-99.4% wt/vol aqueous medium; wherein the composition has an osmolality in the range of 200-1000 mOsm/kg. Also described are methods of making such compositions and method of using such compositions in therapeutic or prophylactic treatment, such as treatments comprising intravenous administration of the pharmaceutical composition.Type: GrantFiled: April 25, 2011Date of Patent: July 1, 2014Assignee: Besins Healthcare Luxembourg SarlInventors: Georg Achleitner, Eva-Maria Hoiser, Laura Pickersgill
-
Patent number: 8759329Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gen formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.Type: GrantFiled: March 14, 2013Date of Patent: June 24, 2014Assignees: Unimed Pharmaceuticals, LLC, Besins Healthcare Luxembourg SARLInventors: Ramana Malladi, Jodi Stahlman
-
Patent number: 8754070Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gel formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.Type: GrantFiled: March 14, 2013Date of Patent: June 17, 2014Assignees: Unimed Pharmaceuticals, LLC, Besins Healthcare Luxembourg SARLInventors: Ramana Malladi, Jodi Stahlman